MarginsXMarginsX
Home › Markets › Health Care › EIKN

Eikon Therapeutics Inc. (EIKN)

EIKN trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$5.38
-9.95% on the day
Market cap
$291.8M
Micro cap
Revenue
New registrant: no annual report filed under this company yet
Net income
New registrant: no annual report filed under this company yet

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerEIKN on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2026
SEC CIK0001861123
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials

New registrant: no annual report filed under this company yet.

Warning signs

Cash runway
4.2 months
$98.5M cash at September 30, 2026
Share count, 1 year
No year-earlier count
Going-concern doubt
No
10-Q filed November 12, 2026
Insider net buying, 12 months
$44.7M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-12
Cash and burn$98.5M cash; operating cash flow -$70.9M a quarter.Report 2026-09-30
Shares outstanding54,186,095 (2026-11-02).Cover page 2026-11-02
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers LLP, San Jose, California, United StatesPCAOB Form AP 2026-04-08
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $44.7M, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$86.1M-$69.2M$98.5MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q3 2026
2026-06-30
Not filed-$88.4M-$65.0M$142.6MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q3 2026
2026-03-31
Not filed-$83.0M-$89.8M$161.2MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q3 2026
2025-09-30
Not filed-$71.1M-$59.5M$104.9MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q3 2026
2025-06-30
Not filed-$105.2M-$32.7M$136.6MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q3 2026
2025-03-31
Not filed-$68.2M-$54.5M$204.6MNo debt tagsNeeds four quarters10-Q 2026-11-12

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B42026-02-05
Latest annual report10-K2026-03-30
Latest quarterly / interim10-Q2026-11-12
Latest current report8-K2026-11-12

Source: SEC EDGAR submissions feed, 69 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+1.4%
1 month-11.0%
3 months-42.1%
Year to dateNot enough price history
1 yearNot enough price history
From 52-week high-63.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
SCTXScribe Therapeutics Inc.$15.37-6.05%$291.1M
AGMBAgomAb Therapeutics NV$5.97-6.13%$294.0M
XFORX4 Pharmaceuticals Inc.$2.83-9.29%$289.0M
EDITEditas Medicine Inc.$1.87-13.82%$288.6M
TRXBTRex Bio Inc.$10.77-21.21%$295.6M
IPSCCentury Therapeutics Inc.$1.64-0.61%$297.8M
AGENAgenus Inc.$6.29-6.54%$284.6M
KYTXKyverna Therapeutics Inc.$4.76-5.74%$300.9M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier